NEW YORK (GenomeWeb News) – Cepheid said today that the US Food and Drug Administration has categorized Cepheid's Xpert MTB/RIF test as "moderate complexity" under CLIA guidelines.

Xpert MTB/RIF runs on Cepheid's GeneXpert system and is designed for the rapid molecular detection of Mycobacterium tuberculosis complex DNA and rifampin-resistance associated mutations of the rpoB gene. The assay provides results in two hours, compared to up to three months with traditional methods of detecting drug-resistant TB, according to Cepheid.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.